Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Professor"

386 News Found

Universal vaccination for Covid-19 irrational: AIIMS Professor
News | February 03, 2022

Universal vaccination for Covid-19 irrational: AIIMS Professor

The need is to vaccinate people who have not contracted Covid-19


Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF
Drug Approval | October 14, 2025

Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF

IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels


Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
Clinical Trials | October 13, 2025

Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma


Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
People | October 13, 2025

Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026


Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis
News | October 09, 2025

Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis

Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis


VectorBuilder Redefines Plasmid Standards with miniVec
R&D | October 08, 2025

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively


Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Clinical Trials | October 01, 2025

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine


DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
Biotech | September 29, 2025

DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland

The new site enables end-to-end production of viral vector gene therapies


Teva unveils promising SOLARIS resultsfor Olanzapine LAI
Clinical Trials | September 23, 2025

Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks


AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
Clinical Trials | September 18, 2025

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo